Carl Cadregari


Expert highlights cybersecurity regulation updates for health care organizations

There have been several recent regulatory updates related to cybersecurity in health care.

Andrew M. Wood, MD


iRARC adoption is slow but persistent in bladder cancer

"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.

Andrew Radtke, MD


Going “retro”: A perspective on robotic retroperitoneal renal surgery

Improvements in technology have renewed interest in the technique.

Stephen A. Boorjian, MD


Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.

Caroline Seymour


Advantages and limitations of AI in prostate cancer

Interest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.

Matthew Smith, MD, PhD


Future Directions in Prostate Cancer Treatment

Drs Smith and Helfand look ahead and provide their thoughts on future directions in the treatment of patients with prostate cancer.

Janelle Hart


Asked by a Resident: Dr. Efe Chantal Ghanney Simons interviews Dr. Mark S. Litwin

"The most important thing I feel I've learned in my life so far is the value of human interaction and human connection," says Mark S. Litwin, MD, MPH.

Brian Helfand, MD, PhD


The Role for PSMA-PET Imaging in Active Surveillance

Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.

Ryan A. Hankins, MD


Multidisciplinary Care in Prostate Cancer

In the second article of this series, Ryan A. Hankins, MD, and Sean P. Collins, MD, PhD, discuss multidisciplinary care practices in prostate cancer, with a focus on communication across specialties.

Anurag Lal


5 ways health care practices can mitigate cyberattack risk

In the world of health care, factors such as remote care, complex IT environments, and connected health care devices are creating new avenues for cybercriminals to target.

Kathleen M. Olson, MD


Urologic implications of Lynch syndrome

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.

Rachelle Manookian, MS, CGC


What is genetic discrimination, and why does it matter?

Fear of discrimination has downstream effects on health care.

Manny Krakaris


Expert shares advice for ethical adoption of AI in health care

“Responsible application of AI is crucial, especially when the health and well being of people are at stake,” writes industry expert Manny Krakaris.

Amanda Hill, JD


Strategies for dealing with difficult patients

In this article, an expert addresses the most common issues that come up with patients that may make them harder to deal with and solutions that may help a provider.

Rainjade Chung, MD


Management of hormone-naïve oligometastatic prostate cancer

Growing evidence supports the existence of an intermediate metastatic disease state.

Steven P. Mathew, PharmD


Drug interactions to monitor when prescribing erectile dysfunction medications

Many of the medications used in the treatment of ED have interactions with other medications, so it is crucial to carefully examine patient profiles to optimize therapy and ensure safety.

Kevin D. Benson, MD, MS


Enhancing Patient-Centric Management in OAB in 2024 and Beyond

Panelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.

Michigan Institute of Urology


Michigan Institute of Urology opens dedicated outpatient medical center for minimally invasive health care

The center will offer a comprehensive range of treatments, including prostate artery embolization for men suffering from benign prostatic hyperplasia with very large prostates.

Tarik Benidir, MD


The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy

"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.

Mark D. Tyson, MD, MPH


Forward Looking NMIBC Treatment Advancements and Needs in 2024

In this final episode, panelists conclude with reflections on the significant progress made in treating NMIBC over the past decade, particularly in the last 5 years. Looking ahead to 2024, experts in urology express excitement about investigational treatments (ie, cretostimogene grenadenorepvec and UGN 102), the potential for personalized medicine, emphasizing the need to understand molecular characteristics of the disease for better treatment customization. The session also highlights the importance of balancing quality of life with effective treatment strategies, and the prospect of utilizing emerging therapies early in the disease process.

Northwestern Medicine


As Patients Live Longer, New Criteria Needed for Prostate Cancer Trials

Researchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.

Matthew Fowler


Encouraging antitumor activity seen with neoadjuvant enfortumab vedotin in patients with cisplatin-ineligible MIBC

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.

Courtney Marabella


Update offers clues to optimal olaparib use in prostate cancer

The latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.

Logan Lutton


Coaching program aims to alleviate female physician burnout

Cofounders Adrienne Mann, MD, and Tyra Fainstad, MD, discuss Better Together, a professional, structured coaching program designed to address the burnout experienced by women in medicine.

Darlene Dobkowski, MA


Darolutamide linked to fewer hospitalizations in patients with mHSPC

Compared with placebo, darolutamide was associated with a numerically lower rate of hospitalizations when combined with androgen-deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer.

Anthony Brooks, MD


Fertility preservation in patients with testicular cancer

"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.

© 2024 MJH Life Sciences

All rights reserved.